- Home
- BCG vs NXTC Comparison
BCG vs NXTC Comparison
Compare BCG & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCG
- NXTC
- Stock Information
- Founded
- BCG 2016
- NXTC 2015
- Country
- BCG United States
- NXTC United States
- Employees
- BCG N/A
- NXTC N/A
- Industry
- BCG
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- BCG
- NXTC Health Care
- Exchange
- BCG Nasdaq
- NXTC Nasdaq
- Market Cap
- BCG 29.6M
- NXTC 24.6M
- IPO Year
- BCG N/A
- NXTC 2019
- Fundamental
- Price
- BCG $3.11
- NXTC $13.91
- Analyst Decision
- BCG
- NXTC Strong Buy
- Analyst Count
- BCG 0
- NXTC 3
- Target Price
- BCG N/A
- NXTC $23.00
- AVG Volume (30 Days)
- BCG 2.1M
- NXTC 53.3K
- Earning Date
- BCG 11-13-2025
- NXTC 11-05-2025
- Dividend Yield
- BCG N/A
- NXTC N/A
- EPS Growth
- BCG N/A
- NXTC N/A
- EPS
- BCG 0.04
- NXTC N/A
- Revenue
- BCG $178,203,000.00
- NXTC N/A
- Revenue This Year
- BCG N/A
- NXTC N/A
- Revenue Next Year
- BCG N/A
- NXTC N/A
- P/E Ratio
- BCG $83.56
- NXTC N/A
- Revenue Growth
- BCG 10.19
- NXTC N/A
- 52 Week Low
- BCG $1.36
- NXTC $2.69
- 52 Week High
- BCG $6.00
- NXTC $15.74
- Technical
- Relative Strength Index (RSI)
- BCG 68.66
- NXTC 67.84
- Support Level
- BCG $2.14
- NXTC $9.21
- Resistance Level
- BCG $2.68
- NXTC $15.74
- Average True Range (ATR)
- BCG 0.39
- NXTC 1.28
- MACD
- BCG 0.17
- NXTC 0.35
- Stochastic Oscillator
- BCG 78.68
- NXTC 71.75
About BCG Binah Capital Group Inc. Common Stock
Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.